Cardiol Therapeutics Inc.

NASDAQ:CRDL

Drug Manufacturers - Specialty & Generic

Healthcare
$0.95 -0.47%

-$0.01 today

Market cap
$114.64M
Beta
0.80
P/E (TTM)
-4.5
EPS (TTM)
-$0.33
52W Low $0.88High $1.71

Volume 0.31M

Average 0.68M

CRDL Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Cardiol Therapeutics Inc.NASDAQ: CRDL

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 108.99M shares rose 31.9% year over year, ahead of the +29.4% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 8.7% from the prior quarter. Over 3 fiscal years it compounded at +11.6% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +31.9% holds above the trailing-twelve-month pace of +29.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
108.99M+8.7% QoQ
Last fiscal yearDec 2025
86.99M+21.5% YoY
LTMMar 2026
94.16M+29.4% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+31.9%——
1 year+21.5%——
3-year CAGR+11.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
86.99M CAD
Year-over-year change
+21.5%
4-year CAGR
+19.1%

Weighted Avg Shares vs competitors

How CRDL compares with its peers on the latest reported figures

  • CRDL's LTM Mar 2026 weighted avg shares of 94.16M shares is the highest of the 10 companies compared; the peer median is 54.72M shares.
  • Its year-over-year change of +29.4% is the 3rd highest of 10, against a peer median of +14.6%.
  • Over three fiscal years its annual growth of +11.6% compares with a peer median of +15.0%.
CRDL Competitors Peer median
Weighted Avg Shares for CRDL and competitors
Company Period LTM YoY 3-year CAGR
CRDLCardiol Therapeutics Inc.LTM Mar 202694.16M +29.4%+11.6%
HYPRHyperfine, Inc.LTM Mar 202687.25M +18.9%+10.2%
IFRXInflaRx N.V.LTM Mar 202668.77M +14.6%+15.0%
VANIVivani Medical, Inc.LTM Mar 202665.65M +15.7%+17.7%
CNTBConnect Biopharma Holdings LimitedFY202555.66M +0.8%+0.4%
MBOTMicrobot Medical Inc.LTM Mar 202654.72M +234.9%+84.8%
INCRInterCure Ltd.LTM Jun 202550.36M +8.8%+7.8%
KLRSKalaris Therapeutics IncLTM Mar 202621.01M +341.4%+66.1%
IMAImageneBio IncLTM Mar 202619.79M -59.0%-48.8%
ASRTAssertio Holdings, Inc.LTM Mar 20266.42M +0.9%+26.9%
Peer median (excluding CRDL) 54.72M+14.6%+15.0%

Competitors are the stored peer set for CRDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue62.27K0000
Cost of Revenue174.26K162.23K187.38K00
Gross Profit(112K)(162.23K)(187.38K)00
Gross Margin-179.9%————
Research & Development8.59M13.99M10.73M14.01M14.02M
Selling, General & Admin21.86M16.34M11.55M25.89M20.2M
Operating Expenses30.46M30.33M22.29M40.28M34.32M
Depreciation & Amortization174.26K162.23K187.38K162.11K101.98K
EBITDA(24.84M)(22.66M)(21.04M)(36.52M)(33.72M)
EBITDA Margin-39891.0%————
Operating Income(30.57M)(30.49M)(22.47M)(40.28M)(34.32M)
Operating Margin-49092.4%————
Interest Income106K1.24M2.04M1.19M726.4K
Interest Expense00000
Other Income / Expenses5.56M7.68M1.25M3.6M497.42K
Income Before Tax(25.01M)(22.82M)(21.22M)(36.68M)(33.82M)
Pre-Tax Margin-40170.9%————
Income Tax Expense00000
Net Income(25.01M)(22.82M)(21.22M)(36.68M)(33.82M)
Net Margin-40170.9%————
EPS (Basic)(0.73)(0.49)(0.44)(0.51)(0.39)
EPS (Diluted)(0.73)(0.49)(0.44)(0.51)(0.39)
Weighted Avg Shares43.22M62.51M64.46M71.57M86.99M
Weighted Avg Shares (Diluted)43.22M62.51M64.46M71.57M86.99M

Cardiol Therapeutics Inc.

NASDAQ:CRDL

Intrinsic Alpha fair value

Locked

Current Price

$0.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.